On April 19th, the "Forum on the Internationalization of TCM Regulation and Achievement Transformation," hosted by the University of Macau and organized by AiSheKang (Shanghai) Health Consulting Co., Ltd., successfully concluded. As a professional force deeply involved in the commercialization and industrialization of biopharmaceuticals, Xinghan Biotechnology was honored to be invited to attend. Mr. Liu Weimin, Vice President of the company, was invited to attend and serve as a panelist for the roundtable discussion, and he attended with many entrepreneur partners to jointly explore effective paths for international expansion.

This forum focused on two core directions: "Internationalization of TCM Regulation" and "Transformation of University Achievements," bringing together regulatory government representatives, top universities, research institutes, and industry representatives from mainland China, Hong Kong, Macao, Singapore, and Indonesia. The event aims to explore feasible paths for Macao as a gateway for international cooperation in TCM, promote the deep integration of industry, academia, and research in TCM, and facilitate the landing of innovative achievements, thereby assisting the high-quality global development of the TCM industry.

During the forum, several roundtable discussions were held around topics such as international cooperation, capital matchmaking, and cultural reshaping. The specially organized "Practical Implementation of Industry-Academia-Research" session witnessed the signing ceremony of the University of Macau's Innovation and Entrepreneurship Center and the roadshows of four outstanding startup projects, providing a practical platform for the industrialization of scientific research achievements from the laboratory.

In the second roundtable discussion, "Unblocking the Innovation Chain: Capital Dialogue and Transformation Breakthroughs in TCM Industry-Academia-Research," Mr. Liu Weimin, Vice President of Xinghan Biotechnology, as an industry representative, engaged in a dialogue with academic, investment, and research experts from the University of Macau, Hengqin Research Institute, Ransheng Industrial, Fuxian Capital, and Rehearth Institute.

Mr. Liu Weimin shared Xinghan's industry practices and thoughts on key topics such as "How Biotechnology Capital Can Empower Early R&D and Industrialization of Traditional Chinese Medicine" and "Risk and Opportunity Assessment in Industry-Academia-Research Cooperation." He pointed out that in the wave of modernization and internationalization of Traditional Chinese Medicine, professional biotechnology enterprises play the role of a "key bridge" connecting cutting-edge scientific research achievements with large-scale market applications. Effective capital intervention should not be limited to financial support, but also requires a deep understanding of scientific research laws, participation in transformation path design, and integration of industry chain resources, so as to achieve a value closed loop from the laboratory to the bedside.

This high-level international forum provided Xinghan Biotechnology with a valuable opportunity for in-depth exchanges with global regulatory agencies, academic leaders, and investment partners. We sincerely thank the organizers for their meticulous organization and invitation, allowing industry voices to be fully expressed on a platform where policy and academia intersect.

Through this event, Xinghan not only showcased its professional insights in biopharmaceutical investment and industrialization to the industry but also established extensive connections with potential partners from multiple countries and regions. In the future, Xinghan will continue to uphold the philosophy of "Connecting Science, Empowering Health," deeply participate in the modernization and internationalization of Traditional Chinese Medicine (TCM), actively empower the transformation of cutting-edge scientific research achievements, and work hand in hand with partners from all sectors to jointly promote the innovative development of the big health industry.